Physician profile
Nicholas Lin
NPI 1417168998
$529.97
in general payments reported to CMS, 2019-2025
12 companies · $27.84 in 2025
The $27.84 reported for 2025 was less than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $17.43 · 2021: $24.00 · 2022: $52.11 · 2023: $29.51 · 2024: $50.05 · 2025: $27.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $149.26 | 2019-2023 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $49.33 | 2022-2025 | Gardasil 9 |
| Sanofi Pasteur INC. | $39.68 | 2019 | |
| Abbvie INC. | $36.56 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $29.67 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.61 | 2019-2020 | |
| Dexcom, INC. | $17.04 | 2022 | |
| Mannkind Corporation | $15.19 | 2019 | |
| Lilly USA, LLC | $13.58 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.49 | 2024 | Airsupra |
| Abbott Laboratories | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.